{"name":"Asofarma de México S.A de C.V.","slug":"asofarma-de-m-xico-s-a-de-c-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CLA (Clarithro+Lanso+Amoxi)","genericName":"CLA (Clarithro+Lanso+Amoxi)","slug":"cla-clarithro-lanso-amoxi","indication":"Helicobacter pylori infection eradication in peptic ulcer disease","status":"phase_3"},{"name":"PLA (Panto+Levoflox+Azithro)","genericName":"PLA (Panto+Levoflox+Azithro)","slug":"pla-panto-levoflox-azithro","indication":"Helicobacter pylori infection eradication","status":"phase_3"}]}],"pipeline":[{"name":"CLA (Clarithro+Lanso+Amoxi)","genericName":"CLA (Clarithro+Lanso+Amoxi)","slug":"cla-clarithro-lanso-amoxi","phase":"phase_3","mechanism":"CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).","indications":["Helicobacter pylori infection eradication in peptic ulcer disease","H. pylori-associated gastritis"],"catalyst":""},{"name":"PLA (Panto+Levoflox+Azithro)","genericName":"PLA (Panto+Levoflox+Azithro)","slug":"pla-panto-levoflox-azithro","phase":"phase_3","mechanism":"PLA is a triple-agent combination that reduces gastric acid (pantoprazole), inhibits bacterial DNA gyrase (levofloxacin), and suppresses protein synthesis (azithromycin) to treat infections and acid-related disorders.","indications":["Helicobacter pylori infection eradication","Acid-related gastrointestinal disorders with concurrent infection"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}